2 results about "Sunitinib" patented technology

The present application belongs to the technical field of biological medicine, and relates to a gene therapy preparation for treating drug-resistant renal cell carcinoma as well as a preparation method and application thereof. It is found for the first time that UBL3 is a key gene for mediating cross-resistance of VEGFR inhibitors of renal cancer, and a lipid nanoparticle composite system integrating specific gene editing and active targeted delivery functions is constructed based on this. The preparation can effectively restore the sensitivity of drug-resistant tumors to first-line drugs such as sunitinib, and shows a significant anticancer effect in in-vivo and in-vitro models, and has important clinical transformation value.

The present application relates to a kind of cell membrane-coated pH-responsive nanogel and its preparation method, the pH-responsive nanogel is that chitosan is crosslinked by crosslinking agent to form nanogel, then load polypeptide ENO1, and further load drug sunitinib, finally, it is prepared by coating kidney cancer cell membrane.The pH-responsive nanogel prepared in the present application as the carrier of polypeptide and drug, with the advantages of good biocompatibility, high drug loading rate, etc., in the tumor microenvironment response dissociation release drug, real-time monitoring is carried out to focus area during treatment.